Kling Biotherapeutics

What Kling Biotherapeutics does

Kling Biotherapeutics is a clinical-stage, privately held biotech company headquartered in Amsterdam, the Netherlands, founded in 2021 to discover and develop antibody-based therapeutics. The company operates a dual-platform discovery engine — Kling-Select (proprietary B-cell immortalization and screening using Bcl-xL/Bcl-6 retroviral transduction) and Kling-Evolve (ex vivo affinity maturation) — that interrogates patient-derived B cells from individuals with exceptional clinical responses to identify novel therapeutic targets and fully human antibodies in a function-first, target-agnostic manner. Kling is advancing an internal pipeline of first-in-class oncology programs, including KBA1412 (anti-CD9, Phase 1 in advanced solid tumors), KBA1413 (anti-CD43-s, AML/MDS), KBA1331 (anti-snRNP200, AML), and KBA1704 (anti-DSG2, colon carcinoma), as well as infectious disease programs targeting RSV, SARS-CoV-2, and influenza.

The company is also the originating platform behind nirsevimab/Beyfortus, the RSV neutralizing antibody marketed by Sanofi and AstraZeneca that is estimated to be a billion-dollar plus product — providing downstream royalty and milestone exposure that validates the platform's commercial potential. Revenue mechanics are concentrated in three streams: licensing royalties from platform-derived products (e.g., Beyfortus), strategic collaboration and license option agreements with pharma partners (exemplified by the Sanofi deal announced July 2025 for neutralizing antibody discovery), and future product sales if internal clinical programs reach approval. Go-to-market is exclusively B2B enterprise via pharmaceutical partnerships and co-development; Kling does not sell or distribute products directly to end customers.

The company is backed by Time BioVentures, with General Partners Tim Wright (Chairman) and D.A. Wallach (Director) on the board. The leadership team combines antibody engineering and clinical development experience drawn from Pfizer, Agenus, Takeda (via GammaDelta), LAVA Therapeutics, Merus, and Molecular Partners. The firm employs 11–50 people and operates from a single site in Amsterdam, with global revenue rights derived from partnership and licensing structures rather than geographic commercial infrastructure.

Name

Kling Biotherapeutics

Legal name

Kling Biotherapeutics B.V.

Website

https://klingbio.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

11–50 employees

Short description

Kling Biotherapeutics is a clinical-stage, Amsterdam-based biotech that discovers first-in-class fully human antibodies and novel therapeutic targets directly from patient-derived B cells using its proprietary Kling-Select and Kling-Evolve platforms, advancing oncology and infectious disease programs while partnering with major pharmaceutical companies.

Ownership category

akta.pro rank

Product category

Biotherapeutics / Antibody Therapeutics

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)

akta.pro secondary industries

Monoclonal Antibody Therapeutics (mAbs) (HLAAAAAA), Protein Interaction & Structural Biology Platforms (cryo-EM, X-ray, NMR, biophysics) (HLAAAIAH)

Keywords

• Antibody therapeutics
• B-cell platform
• Biotherapeutics discovery
• Oncology drug development
• Monoclonal antibodies

Headquarters

HQ city

Amsterdam

HQ country

Netherlands

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Strategic Partnerships and Licensing: Kling generates revenue through collaboration and license option agreements with pharmaceutical companies for antibody discovery services and platform utilization. The Sanofi collaboration (announced July 2025) represents a license option agreement for discovering neutralizing antibodies against a clinically relevant viral pathogen.
2. Platform-Derived Product Royalties: The company benefits from royalties and milestone payments from products discovered using its platform. The RSV antibody nirsevimab/Beyfortus (AstraZeneca/Sanofi) is estimated as a billion-dollar plus product, validating the commercial potential of platform-derived discoveries.
3. Internal Pipeline Development: Clinical-stage company advancing proprietary oncology programs (KBA1412, KBA1413, KBA1331, KBA1704) through clinical development toward commercial products. Future revenue potential from approved therapeutics.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Core offering

Kling Biotherapeutics discovers and develops antibody-based therapeutics using two proprietary platform technologies — Kling-Select (B-cell immortalization and screening) and Kling-Evolve (ex vivo affinity maturation) — to identify novel therapeutic targets and fully human antibodies directly from patient-derived B cells. The company advances a pipeline of oncology programs (KBA1412 in Phase 1 for solid tumors; KBA1413, KBA1331, KBA1704 in preclinical) and infectious disease programs against RSV, SARS-CoV-2, and Influenza, while generating revenue through pharmaceutical collaboration, licensing, and royalties (e.g., the Sanofi agreement and the billion-dollar-plus marketed Beyfortus antibody originating from the platform).

Product overview

Kling Biotherapeutics is a clinical-stage privately held biotech company offering two integrated platform technologies: Kling-Select for simultaneous discovery of novel therapeutic targets and fully human antibodies from patient-derived B cells, and Kling-Evolve for ex vivo affinity maturation of antibody candidates. The company is advancing a pipeline of oncology programs including KBA1412 (anti-CD9 antibody in Phase 1 for solid tumors), KBA1413 (anti-CD43-s for AML), KBA1331 (anti-snRNP200 for AML), and KBA1704 (anti-DSG2 for colon carcinoma), as well as infectious disease programs including neutralizing antibodies against RSV, COVID-19, and Influenza. The platform has already produced the commercially validated RSV antibody nirsevimab (Beyfortus).

Differentiator

Problem solved

Functional benefit

Products and services

• Kling-Select Proprietary B-cell immortalization and screening platform using Bcl-xL and Bcl-6 retroviral transduction of memory B cells to generate stable patient-derived B-cell libraries; enables target-agnostic discovery of novel therapeutic targets and fully human antibodies from patients with exceptional clinical responses. Offered as a platform capability within the company's pipeline and partnership model.
• Kling-Evolve Ex vivo affinity maturation technology that preserves activation-induced somatic hypermutation in immortalized B cells, enabling continuous evolution of antibody clones for increased affinity, selectivity, and reactivity against alternative target variants. Used for rapid evolution of neutralizing antibodies against emerging viral variants and for affinity/selectivity improvement of oncology assets.
• KBA1412 First-in-class, fully human anti-CD9 antibody developed from B cells of a cancer survivor; currently in a Phase 1/1b clinical trial for treatment of advanced solid tumors not responding to standard of care. Represents Kling's lead clinical-stage oncology asset.
• KBA1413 Anti-CD43-s antibody derived from an AML survivor that recognizes an AML-specific CD43 glycoepitope; shows activity against AML, MDS, and solid cancer cells. Preclinical-stage oncology program targeting hematologic malignancies.
• KBA1331 Anti-snRNP200 antibody identified from multiple AML survivors that binds to an ectopic antigen on AML cells. Preclinical-stage oncology program for acute myeloid leukemia.
• KBA1704 Anti-DSG2 (anti-Desmoglein 2) antibody derived from a Lynch syndrome/colon carcinoma responder. Preclinical-stage oncology program targeting Desmoglein 2 in colon carcinoma.
• SARS-CoV-2 Neutralizing Clones Stable B-cell clones selected against SARS-CoV-2 virus using the Kling-Select and Kling-Evolve platforms, with ongoing development for broad variant coverage including Delta, BA.5, and emerging lineages. Preclinical-stage infectious disease program.
• Influenza Neutralizing Clones Stable B-cell clones selected against influenza virus using the Kling-Select platform, identified for potential therapeutic development against influenza. Preclinical-stage infectious disease program.

Quantifiable outcome

• Discovery of monoclonal antibodies from primary B cells in as little as three weeks
• +3 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• SanoficoreStrategic or Co-development Partner · 24 July 2025Kling Bio announced a collaboration and license option agreement with Sanofi for the discovery of antibodies and epitopes using its Kling-Select platform. The objective is to identify and characterize monoclonal antibodies with potent neutralizing activity against a clinically relevant human viral pathogen. Sanofi will have an option to license discovered antibodies and epitopes for further development. Insights from this joint discovery effort may enable development of next-generation antiviral therapeutics and inform vaccine design.

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• AbCellera Biologics: Public antibody discovery platform using single-cell B-cell screening to identify therapeutic antibodies — directly comparable to Kling's Kling-Select approach, with established pharma partnerships (e.g., Eli Lilly) and a similar target-agnostic value proposition.
• Merus N.V. Dutch clinical-stage bispecific antibody developer (Biclonics platform) — comparable as a Netherlands-based antibody platform company; notably Rob Roovers (Kling's Director of Preclinical Development) co-developed Merus bispecifics nearing registration.
• Adimab: Private antibody discovery and engineering platform offering partners access to a proprietary yeast-based library for therapeutic antibody generation — competes with Kling-Select on speed, library diversity, and pharma partnership economics.
• Crescendo Biologics: Clinical-stage T cell engager (TCe) platform company developing multi-specific antibodies — comparable to Kling as a European clinical-stage antibody platform company with proprietary discovery technology and oncology focus.
• Molecular Partners: Swiss clinical-stage biotech developing DARPin-based therapeutics for oncology and infectious disease — comparable as a small-cap European biologics platform company; Alessandra Micaela Villa (Kling's Director of Platform Development) previously led antibody research at Molecular Partners.
• Ablexis (Harbour Biomed): Antibody platform company offering the AlivaMab Mouse and discovery technologies for therapeutic antibody generation — comparable to Kling as a platform-enabled antibody discovery business with licensing and partnership revenue.

Emerging players

• Compugen: Israel-based computational biology company using AI/ML to predict and discover novel antibody targets — adjacent peer as an emerging computational antibody discovery platform with similar target-agnostic ambitions, though leveraging in silico rather than B-cell-based discovery.

Broad incumbents

• Argenx: Public clinical-stage and commercial-stage antibody therapeutics company with the Antibody Simple Commons platform and approved products (Vyvgart) — comparable as a successful European antibody platform company, though now considerably larger and more commercial than Kling.
• Regeneron Pharmaceuticals: Large-cap antibody therapeutics leader operating the VelocImmune platform (which produced nirsevimab alongside Kling's technology) — directly relevant as the co-developer of Beyfortus and as a broad incumbent in antibody discovery and engineering.
• Genmab: Large publicly traded antibody therapeutics company with the DuoBody bispecific platform and approved products (e.g., Darzalex, Tezspire) — comparable as a broad incumbent in therapeutic antibody development, though with much greater scale and a more commercial-stage business model.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Kling Biotherapeutics